Zepbound Cost in Nevada (2026): Cash Price, Insurance, and Compounded Options

Nevada Retail Pricing for Zepbound in 2026

The average cash price for Zepbound at Nevada retail pharmacies sits at $1,059 per month in 2026, matching Eli Lilly's national list price. This figure applies across all dose strengths (2.5 mg through 15 mg) because Eli Lilly uses a flat monthly pricing model for the drug.

Price variation between individual Nevada pharmacies is minimal for brand-name Zepbound. Chains like CVS, Walgreens, and Walmart locations in Las Vegas, Reno, and Henderson quote within a narrow band of the list price. Independent pharmacies occasionally offer slightly lower dispensing fees, but the drug acquisition cost remains fixed by the manufacturer.

The $1,059 figure represents the wholesale acquisition cost (WAC) that Eli Lilly sets nationally. No generic version of tirzepatide exists as of May 2026, and Eli Lilly holds patent protection on the molecule. For patients paying entirely out of pocket, this translates to roughly $12,708 per year, a figure that places Zepbound in line with other GIP/GLP-1 receptor agonists in the branded obesity pharmacotherapy class.

Tirzepatide earned FDA approval for chronic weight management under the brand name Zepbound in November 2023, based on data from the SURMOUNT clinical trial program. In SURMOUNT-1 (N=2,539), participants receiving the highest dose of tirzepatide (15 mg) achieved 22.5% mean body weight reduction at 72 weeks compared to 3.1% with placebo [1]. That degree of efficacy is what drives both patient demand and the premium price point.

Nevada Medicaid and Zepbound Coverage

Nevada Medicaid does not cover Zepbound for chronic weight management. This mirrors a broader national pattern: most state Medicaid programs exclude anti-obesity medications from their formularies, citing the federal Medicaid Drug Rebate Program's historical exclusion of weight-loss drugs.

The distinction matters. Tirzepatide is also marketed as Mounjaro for type 2 diabetes, and Nevada Medicaid does cover Mounjaro for that indication. But the same molecule prescribed under the Zepbound label for weight management falls outside the benefit. Patients with both obesity and type 2 diabetes may have a pathway to tirzepatide coverage through the Mounjaro indication, provided their prescriber documents the diabetes diagnosis as the primary treatment rationale.

The Endocrine Society's 2024 clinical practice guidelines recommend pharmacotherapy for patients with BMI ≥30 or BMI ≥27 with weight-related complications, positioning tirzepatide as a first-line option based on SURMOUNT trial data [2]. Despite this guideline endorsement, Medicaid coverage decisions in Nevada remain driven by the state's pharmacy and therapeutics committee, which has not added Zepbound to the preferred drug list.

Nevada residents enrolled in Medicaid who want to pursue tirzepatide for weight management have limited options: apply for a prior authorization exception (rarely granted), switch to a covered alternative like oral semaglutide if formulary-listed, or pay out of pocket through cash-pay or compounding pathways described below.

Commercial Insurance Coverage in Nevada

Commercial insurance plans in Nevada vary widely on Zepbound coverage. Some plans administered by Blue Cross Blue Shield of Nevada, UnitedHealthcare, and Aetna include anti-obesity medications on their formularies. Others exclude the entire drug class.

For plans that do cover Zepbound, expect a prior authorization requirement. Typical criteria include documented BMI ≥30 (or ≥27 with a comorbidity such as hypertension, dyslipidemia, or obstructive sleep apnea), evidence of a failed lifestyle intervention lasting 3 to 6 months, and prescriber attestation that the patient meets FDA label criteria. Tier placement is usually specialty (Tier 4 or 5), which means coinsurance of 25% to 50% rather than a flat copay.

A patient with a plan that covers Zepbound at 30% coinsurance would owe roughly $318 per month before any manufacturer assistance. That figure drops substantially with the Eli Lilly Zepbound Savings Card, which reduces the copay to as low as $25 per month for eligible commercially insured patients. The savings card caps total annual benefit at $150 per monthly prescription for up to 12 months [3].

Self-funded employer plans (ERISA plans) add another layer of complexity. These plans are not regulated by the Nevada Division of Insurance and can exclude obesity medications at the employer's discretion. Nevada state employees on the Public Employees' Benefits Program (PEBP) should check the current formulary directly, as coverage for GLP-1 class medications has been reviewed multiple times in the past 18 months.

Compounded Tirzepatide in Nevada: Legality and Pricing

Compounded tirzepatide is available in Nevada through licensed 503A compounding pharmacies at approximately $249 per month. This represents a 76% discount compared to brand-name Zepbound.

The legality question is straightforward. Under federal law, 503A pharmacies may compound tirzepatide pursuant to a valid patient-specific prescription when a prescriber determines it is medically appropriate. The FDA's enforcement discretion regarding compounded tirzepatide has evolved since Zepbound's launch. As of early 2026, 503A compounding remains a legal pathway in Nevada, provided the pharmacy holds a valid Nevada State Board of Pharmacy compounding license and operates within the scope of section 503A of the Federal Food, Drug, and Cosmetic Act [4].

Key distinctions for Nevada patients considering compounded tirzepatide:

• 503A pharmacies compound patient-specific prescriptions. The prescriber must have a direct patient relationship. These pharmacies are regulated by the Nevada State Board of Pharmacy.
• 503B outsourcing facilities produce larger batches without patient-specific prescriptions. Fewer 503B facilities compound tirzepatide, and their regulatory pathway differs.
• Compounded tirzepatide is not FDA-approved and does not undergo the same bioequivalence testing as Zepbound. Purity, potency, and sterility depend on the compounding pharmacy's quality controls.

Pricing at Nevada 503A pharmacies ranges from $199 to $349 per month depending on dose strength, with most patients at maintenance doses (10 mg or 15 mg weekly) paying near the $249 average. Some telehealth platforms that partner with compounding pharmacies bundle the consultation fee into the monthly price, offering all-inclusive packages between $299 and $399 per month.

Dr. Caroline Apovian, a professor at Harvard Medical School and co-author of the Endocrine Society's obesity guidelines, has noted: "Compounded GLP-1 agonists fill an access gap for patients who cannot afford branded medications, but patients should verify their pharmacy's accreditation and compounding standards" [5].

How the Eli Lilly Zepbound Savings Card Works in Nevada

Eli Lilly's manufacturer savings card is one of the most direct ways to reduce Zepbound costs for commercially insured Nevada residents. The card is not available to patients on government insurance (Medicare, Medicaid, Tricare, VA).

Here is how the program functions:

• Eligible patients with commercial insurance that covers Zepbound may pay as low as $25 per fill.
• Patients whose commercial insurance does not cover Zepbound (or who face a coverage gap) can use the savings card to pay a reduced out-of-pocket price, though the discount amount differs from the insured tier.
• The card is activated through Lilly's official Zepbound website and presented to the pharmacy at the point of sale.
• Maximum benefit per fill and annual caps apply. Program terms are subject to change, and Eli Lilly has adjusted cap amounts multiple times since launch.

Nevada pharmacies process the savings card as a secondary payer after the primary insurance adjudicates the claim. If the primary plan rejects the claim entirely, some pharmacies can still run the savings card as a standalone discount, though the resulting price is higher than the $25 insured-tier price.

One practical consideration: not every Nevada pharmacy participates in the program. Large chains generally do, but patients should confirm participation before filling. The savings card does not apply at compounding pharmacies or to compounded tirzepatide.

Telehealth Access to Zepbound in Nevada

Nevada permits telehealth prescribing of Zepbound. The state's telehealth laws, updated through Assembly Bill 131 and subsequent regulations, allow licensed prescribers to evaluate patients and write prescriptions for controlled and non-controlled substances via synchronous audio-video visits.

Multiple national telehealth platforms operate in Nevada and prescribe Zepbound or compounded tirzepatide. These platforms typically employ or contract with physicians and nurse practitioners licensed in Nevada. The workflow involves an initial video consultation, lab review (many platforms require recent metabolic labs including A1c, lipid panel, and comprehensive metabolic panel), and then ongoing monthly check-ins.

Costs through telehealth platforms break down into two models:

Brand Zepbound via telehealth: The platform charges a consultation fee ($49 to $149 for the initial visit, $29 to $99 for follow-ups), and the patient fills the prescription at a retail pharmacy using insurance or the savings card. Total monthly cost equals the consultation fee plus the pharmacy cost.

Compounded tirzepatide via telehealth: The platform bundles the consultation and medication into a single monthly fee, typically $299 to $399. The compounded medication ships directly to the patient from a partnered 503A pharmacy.

For Nevada residents outside the Las Vegas and Reno metro areas, telehealth removes a significant geographic barrier. Rural Nevada has limited endocrinology and obesity medicine specialist access, and telehealth platforms provide a pathway to evidence-based pharmacotherapy regardless of location.

Comparing All Nevada Pricing Pathways

Different financial situations call for different strategies. A side-by-side comparison clarifies the options:

Cash pay at retail pharmacy: $1,059 per month. No insurance needed. Full Eli Lilly pricing. Patient can use GoodRx or similar discount cards, though savings on Zepbound specifically are minimal (typically $1,020 to $1,059 range).

Commercial insurance with savings card: $25 to $318 per month depending on plan coinsurance and savings card eligibility. Requires prior authorization in most cases.

Compounded tirzepatide (503A): $199 to $349 per month. Requires a valid prescription. Not FDA-approved. Quality depends on pharmacy accreditation.

Telehealth plus compounded tirzepatide bundle: $299 to $399 per month. Includes consultation and medication. Convenient for patients without a local prescriber.

Patient assistance (LillyDirect): Eli Lilly's direct-to-patient program offers Zepbound at $399 per month for self-pay patients without using insurance. This program launched in 2024 and ships medication directly [6].

The CDC reports that 34.4% of Nevada adults have obesity, ranking the state 29th nationally [7]. That prevalence translates to roughly 750,000 Nevadans who could meet BMI-based eligibility criteria for Zepbound, creating substantial demand across all pricing tiers.

Clinical Context: What You Get for the Cost

The price of Zepbound reflects a drug with the highest weight-reduction efficacy in its class. Understanding the clinical data helps contextualize the cost.

In SURMOUNT-1, tirzepatide 15 mg produced 22.5% mean weight loss at 72 weeks. The 10 mg dose produced 21.4%, and the 5 mg dose produced 16.0%, all versus 3.1% for placebo [1]. These results exceeded those of semaglutide 2.4 mg (Wegovy), which produced 14.9% mean weight loss in the STEP-1 trial (N=1,961) over 68 weeks [8].

Tirzepatide's dual mechanism (GIP and GLP-1 receptor agonism) appears to account for the additional efficacy. The GIP component may enhance fat oxidation and improve insulin sensitivity through pathways distinct from GLP-1 alone, according to data published in The Lancet from the SURMOUNT-2 trial in patients with type 2 diabetes and obesity [9].

Common side effects are gastrointestinal: nausea (reported by 24.6% of participants at the 15 mg dose in SURMOUNT-1), diarrhea (18.7%), and constipation (11.7%) [1]. These effects are typically mild to moderate, peak during dose titration, and diminish over weeks. The slow titration schedule (starting at 2.5 mg and increasing every 4 weeks) is designed to minimize GI symptoms.

Dr. Ania Jastreboff, the lead SURMOUNT-1 investigator at Yale School of Medicine, stated: "The magnitude of weight reduction with tirzepatide is unprecedented among approved anti-obesity medications, and the safety profile is consistent with the GLP-1 receptor agonist class" [10].

For a Nevada patient spending $249 per month on compounded tirzepatide or $25 per month with a savings card, the annual cost of $2,988 or $300 respectively buys access to a therapy that clinical trials show can reduce body weight by one-fifth in under 18 months. Whether that represents value depends on individual health economics, but the efficacy data is unambiguous.

Next Steps for Nevada Patients

Start by confirming your insurance formulary status. Call the number on the back of your insurance card and ask specifically whether Zepbound (tirzepatide) is covered under your plan's pharmacy benefit for chronic weight management. If covered, ask about tier placement and prior authorization requirements, then request your prescriber submit the prior authorization with documentation of BMI, comorbidities, and prior lifestyle interventions.

If your plan does not cover Zepbound, activate the Eli Lilly savings card and check eligibility for the $399 per month LillyDirect self-pay option. If cost remains prohibitive, discuss compounded tirzepatide with your prescriber and verify the compounding pharmacy's Nevada Board of Pharmacy license and PCAB accreditation status before filling.